Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy

被引:2
|
作者
Garcia, Cristina Cano [1 ,2 ,18 ]
Flammia, Rocco S. [3 ]
Piccinelli, Mattia [1 ,4 ]
Panunzio, Andrea [1 ,5 ]
Tappero, Stefano [1 ,6 ,7 ]
Barletta, Francesco [1 ,8 ]
Incesu, Reha-Baris [1 ,9 ]
Law, Kyle W. [1 ]
Morra, Simone [1 ,10 ]
Tian, Zhe [1 ]
Saad, Fred [1 ]
Kapoor, Anil [11 ]
Shariat, Shahrokh F. [12 ,13 ,14 ,15 ]
Longo, Nicola [10 ]
Tilki, Derya [16 ,17 ]
Briganti, Alberto [8 ]
Terrone, Carlo [6 ,7 ]
Antonelli, Alessandro [5 ]
De Cobelli, Ottavio [4 ]
Hoeh, Benedikt [2 ]
Kluth, Luis A. [2 ]
Chun, Felix K. H. [2 ]
Karakiewicz, Pierre I. [1 ]
机构
[1] Univ Montreal, Div Urol, Canc Prognost & Hlth Outcomes Unit, Hlth Ctr, Montreal, PQ, Canada
[2] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[3] Sapienza Rome Univ, Policlin Umberto Hosp 1, Dept Maternal Child & Urol Sci, Rome, Italy
[4] IRCCS, IEO European Inst Oncol, Dept Urol, Milan, Italy
[5] Univ Verona, Dept Urol, Azienda Osped Univ Integrata Verona, Verona, Italy
[6] IRCCS Policlin San Martino, Dept Urol, Genoa, Italy
[7] Univ Genoa, Dept Surg & Diagnost Integrated Sci DISC, Genoa, Italy
[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Div Oncol, Unit Urol,Gianfranco Soldera Prostate Canc Lab, Milan, Italy
[9] Univ Hosp Hamburg Eppendorf, Prostate Canc Ctr, Martini Klin, Hamburg, Germany
[10] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Urol Unit, Naples, Italy
[11] McMaster Univ, McMaster Inst Urol, Div Urol, Hamilton, ON, Canada
[12] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[13] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[14] Univ Texas Southwestern, Dept Urol, Dallas, TX USA
[15] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Dept Urol, Amman, Jordan
[16] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[17] Koc Univ Hosp, Dept Urol, Istanbul, Turkiye
[18] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany
关键词
Clear cell; Metastatic renal cell carcinoma; Partial nephrectomy; SEER; Other-cause mortality; OPEN-LABEL; EVEROLIMUS;
D O I
10.1016/j.clgc.2023.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We tested within a large population-based and matched analyses if previously described advantages in othercause mortality (OCM) for clear cell metastatic renal cell carcinoma (ccmRCC) patients undergoing partial cytoreductive nephrectomy (PCN) still apply, relative to radical cytoreductive nephrectomy (RCN). We confirm the existence of OCM advantage after PCN vs. RCN in contemporary ccmRCC patients and PCN may continue being considered as a valuable alternative to RCN, when technically feasible. Background: It is unknown whether previously reported other-cause mortality (OCM) advantage of partial cytoreductive nephrectomy (PCN) vs. radical cytoreductive nephrectomy (RCN) still applies to contemporary clear cell metastatic renal cell carcinoma (ccmRCC) patients. Materials and Methods: We relied on the Surveillance, Epidemiology and End Results (SEER) database (2004-2019) to identify ccmRCC patients treated with PCN and RCN. Temporal trends of PCN rates within the SEER database were tabulated. After propensity score matching (PSM), cumulative incidence plots depicted 5-year OCM and cancer-specific mortality (CSM) of PCN and RCN patients. Multivariable Cox regression models tested for differences between PCN vs. RCN. Results: Of 5149 study patients, 237 (5%) underwent PCN vs. 4912 (95%) RCN. In the SEER database 2004 to 2019, rates of PCN in ccmRCC patients increased from 3.0% to 8.0% (estimated annual percent change [EAPC]: 3.0%; P = .04). After PSM, 5-year OCM rates were 2.4 vs. 7.5% for respectively PCN vs. RCN patients (P = .036). 5-year CSM rates were 50.8 vs. 53.6% for respectively PCN and RCN patients (P = .57). In multivariable Cox regression models, PCN was associated with lower OCM (Hazard Ratio (HR): 0.39; 95% confidence interval (CI): 0.18-0.84; P = .02) but did not affect CSM rates (HR: 0.99; 95% CI: 0.76-1.29; P = .96). Conclusions: We confirm the existence of OCM advantage after PCN vs. RCN in contemporary ccmRCC patients.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [31] TIMING OF CYTOREDUCTIVE NEPHRECTOMY DOES NOT INFLUENCE SURVIVAL IN METASTATIC RENAL CELL CARCINOMA
    Chapin, Brian F.
    Delacroix, Scott E.
    Culp, Stephen H.
    Nogueras-Gonzalez, Graciela M.
    Tannir, Nizar
    Jonasch, Eric
    Tamboli, Pheroz
    Wood, Christopher G.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E705 - E706
  • [32] Lapaloscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
    Fujita, T.
    Hattori, R.
    Kinukawa, T.
    Ono, Y.
    [J]. JOURNAL OF ENDOUROLOGY, 2006, 20 : A231 - A231
  • [33] Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma PRO
    Wood, Christopher G.
    [J]. JOURNAL OF UROLOGY, 2013, 190 (02): : 387 - 388
  • [34] Cytoreductive nephrectomy for metastatic renal cell carcinoma – obsolete?
    Grimm M.-O.
    [J]. Der Urologe, 2019, 58 (1): : 51 - 52
  • [35] Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
    不详
    [J]. JOURNAL OF ENDOUROLOGY, 2005, 19 : A39 - A39
  • [36] Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma
    Finelli, A
    Kaouk, JH
    Fergany, AF
    Abreu, SC
    Novick, AC
    Gill, IS
    [J]. BJU INTERNATIONAL, 2004, 94 (03) : 291 - 294
  • [37] Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
    Bajic, Petar
    Flanigan, Robert C.
    Joyce, Cara J.
    Clark, Joseph I.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (03): : 453 - 454
  • [38] SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?
    Keskin, Sarp
    Petros, Firas
    Yu, Kai-jie
    Aboshady, Yara
    Borregales, Leonardo
    Kenney, Patrick
    Matin, Surena
    Karam, Jose
    Wood, Christopher
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E65 - E66
  • [39] Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology
    Kassouf, Wassim
    Sanchez-Ortiz, Ricardo
    Tamboli, Pheroze
    Tannir, Nizar
    Jonasch, Eric
    Merchant, Madhur M.
    Matin, Surena
    Swanson, David A.
    Wood, Christopher G.
    [J]. JOURNAL OF UROLOGY, 2007, 178 (05): : 1896 - 1900
  • [40] Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study
    Marchioni, Michele
    Bandini, Marco
    Preisser, Felix
    Tian, Zhe
    Kapoor, Anil
    Cindolo, Luca
    Primiceri, Giulia
    Berardinelli, Francesco
    Briganti, Alberto
    Shariat, Shahrokh F.
    Schips, Luigi
    Karakiewicz, Pierre I.
    [J]. EUROPEAN UROLOGY FOCUS, 2019, 5 (03): : 488 - 496